Table 3 Univariate Cox analyses of PFS and OS in training and validation cohorts

PFS

 Gender (Male vs. Female)

0.644(0.421–0.985)

0.042

1.017(0.591–1.747)

0.952

 Age (≤ 55 vs. > 55)

1.754(1.209–2.543)

0.003

1.595(0.938–2.713)

0.085

 Smoke (no vs. yes)

1.177(0.829–1.672)

0.362

1.003(0.633–1.588)

0.991

 Drink (no vs. yes)

0.883(0.463–1.685)

0.707

0.934(0.465–1.876)

0.848

 T stage (T1-T2 vs. T3-T4)

1.825(1.241–2.683)

0.002

1.432(0.897–2.284)

0.132

 N stage (N0-N1 vs. N2-N3)

1.347(0.945–1.919)

0.099

2.102(1.284–3.440)

0.003

 TNM stage (I-II vs. III-IVa)

3.355(1.808–6.228)

 < 0.001

2.456(1.223–4.934)

0.012

 EBV DNA (negative vs. positive)

2.966(1.987–4.425)

 < 0.001

2.992(1.758–5.093)

 < 0.001

 LA (≤ 80.17 vs. > 80.17)

0.495(0.340–0.719)

 < 0.001

0.463(0.287–0.747)

0.002

OS

 Gender (Male vs. Female)

0.802(0.440–1.464)

0.472

0.712(0.296–1.716)

0.449

 Age (≤ 55 vs. > 55)

3.595(2.146–6.021)

 < 0.001

2.910(1.465–5.779)

0.002

 Smoke (no vs. yes)

1.206(0.717–2.027)

0.481

1.366(0.704–2.652)

0.356

 Drink (no vs. yes)

1.200(0.516–2.795)

0.672

1.688(0.737–3.864)

0.216

 T stage (T1-T2 vs. T3-T4)

2.007(1.115–3.614)

0.020

2.583(1.210–5.512)

0.014

 N stage (N0-N1 vs. N2-N3)

1.313(0.776–2.222)

0.311

1.655(0.823–3.326)

0.157

 TNM stage (I-II vs. III-IVa)

8.462(2.065–34.683)

0.003

5.283(1.268–22.022)

0.022

 EBV DNA (negative vs. positive)

2.358(1.326–4.194)

0.004

2.914(1.324–6.416)

0.008

 LA (≤ 80.17 vs. > 80.17)

0.324(0.175–0.601)

 < 0.001

0.219(0.096–0.502)

 < 0.001